Articles By David Liew, FRACP
The path to new technologies in rheumatology must be beset with caution
As we have incorporated technology into our workflows, and consequently saved lives and suffering, we have balanced our excitement about progress with proof that incremental advances can truly deliver benefit. it is easy to let promise carry our caution away - and while most of the time such advances come in a vetted package, which we can consume without concern, conference abstracts come raw. This is the necessary ingredient to a platform which allows for bold ideas and innovation, but for that reason it is not such a curated space. At EULAR 2024, we saw the usual mix of bright, raw ideas on the poster floor emblematic of this paradigm.
Read Article
Choices in GCA
There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.
Read Article
The art of talking about risks with our patients
On the first day of EULAR 2024, I am debating Janet Pope.
Read Article
ICYMI: How do we manage difficult discussions about pregnancy in RA?
Most rheumatologists know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though: the details are difficult, it is overwhelming for the patient, and the conversations are hard.
Read Article
When should we be starting therapy in GCA and PMR?
The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind a shrug of the shoulders, or the ambiguity of therapeutic inadequacy. The question that follows the presence of a therapy is the question as to how to best use it. GCA and PMR are at the stage in the growth of their therapeutic development where this problem is moving to the front of mind, and it made for a fitting topic in the ACR Great Debate. Drs. Rob Spiera and Phil Seo - two luminaries in the vasculitis and PMR worlds - were pitted head to head to discuss.
Read Article
Why are older RA patients getting mistreated?
Most rheumatologists, if asked, would say that every rheumatoid arthritis patient should be started on a DMARD of some sort - if not at diagnosis, then pretty soon after. So I am genuinely shocked that, in a large United States Medicare 20% sample dataset between 2008-17, less than 30% of new RA patients aged 66 years or older have a DMARD initiated.
Read Article
How do we manage difficult discussions about pregnancy in RA?
Most rheumatologists know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though: the details are difficult, it is overwhelming for the patient, and the conversations are hard.
Read Article
JAKi for PMR: Safe, or a Concern for Older Adults?
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider.
Read Article
Zoster protection for JAK inhibitor patients appears achievable
One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.
Read Article
Clinically suspect arthralgias: justified or artefact?
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.
Read Article